×

Biotech and Pharmaceuticals Medicine

  • The Food and Drug Administration on Friday approved the drug for adults with acute myeloid leukemia who have a genetic mutation called FLT3. The drug's maker, Novartis Pharmaceuticals Corp., said it is the first new medicine for the blood cancer in 25 years. Novartis said the list price will be $14,990 for four weeks of treatment.

  • April 28- The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia as well as certain other blood disorders, the agency said on Friday. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.

  • April 28- The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia as well as certain other blood disorders, the agency said on Friday. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.

  • April 28- The U.S. Food and Drug Administration on Friday approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia. AML is a rapidly progressing cancer, which forms in the bone marrow and results in an increased number of white blood cells in the bloodstream. Rydapt has secured approval for adults with newly diagnosed AML that have a...

  • April 21- Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.. Looks like Valeant has sought to price this reasonably relative to Taltz and Cosentyx, Stifel analyst Annabel Samimy told Reuters.

  • April 27- Biomarin Pharmaceuticals Inc said the annual price for its drug, which won U.S. approval on Thursday, to treat a rare and fatal type of pediatric brain disease is expected to be $486,000 after mandatory government discounts and rebates. The Food and Drug Administration approved Brineura, an enzyme replacement therapy, for patients aged 3 and older to...

  • SAN DIEGO _ Tandem Diabetes Care Inc. on Thursday reported a loss of $23.8 million in its first quarter. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 66 cents per share. Seven analysts surveyed by Zacks expected $16.1 million.

  • April 27- The U.S. Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease, an extremely rare disorder that mainly impacts the nervous system. Biomarin said Brineura is expected to be available in the United States by early June and the company will begin promotion of the drug...

  • NEW YORK, April 27- Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs. "Sales for Opdivo were strong despite a more competitive landscape," Chief Executive Officer Giovanni...

  • April 27- The United States Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease, a rare disorder that mainly affects the nervous system and is ultimately fatal. The drug, Brineura, is an enzyme replacement therapy designed to slow loss of walking ability in patients, three years or...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers shares were up 1.9 percent at $54.80 on the New York Stock Exchange. Bristol-Myers reported a profit of $1.57 billion, or 94 cents a share, for the quarter,...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers reported profit of $1.57 billion, or 94 cents a share, in the quarter, up from $1.20 billion, or 71 cents a share, a year earlier. Wall Street analysts, on average,...

  • Sales of Enbrel, faced with increased competition and slowing growth in the rheumatology and dermatology sectors, dropped 15 percent to $1.18 billion, below Wall Street estimates of about $1.38 billion. Total sales fell 1 percent to $5.5 billion, shy of analysts' consensus estimates of $5.6 billion. Excluding items, Amgen had adjusted earnings of $3.15 per...

  • Sales of Enbrel, faced with increased competition and slowing growth in the rheumatology and dermatology sectors, dropped 15 percent to $1.18 billion, below Wall Street estimates of about $1.38 billion. Total sales fell 1 percent to $5.5 billion, shy of analysts' consensus estimates of $5.6 billion. It raised the low end of its adjusted 2017 earnings forecast by...

  • Sales of Enbrel, faced with increased competition and slowing growth in the rheumatology and dermatology sectors, dropped 15 percent to $1.18 billion, below Wall Street estimates of about $1.38 billion. Total sales for the quarter fell 1 percent to $5.5 billion, shy of analysts' consensus estimates of $5.6 billion. It raised the low end of its adjusted 2017...

  • BOSTON— Researchers have taken an important step toward better lung cancer treatment by using blood tests to track genetic changes in tumors as they progress from their very earliest stages. With experimental tests that detect bits of DNA that tumors shed into the blood, they were able to detect some recurrences of cancer up to a year before imaging scans could,...

  • Celgene exec. chair: Trump administration will listen to reccomendations from the industry

    CNBC's Meg Tirrell speaks with Robert Hugin, Celgene executive chairman, about the outlook for the pharmaceutical industry under the Trump administration.

  • Gabriella Corley

    Soaring insulin prices and inflexible insurance policies have forced many parents to take desperate measures to keep their kids alive.

  • The pills, creams and teas are untested and not approved by the FDA, which called them a "cruel deception." The FDA on Tuesday posted the warning letters it sent to 14 manufacturers, telling them to remove their fraudulent claims describing the products as drugs, or face stiff penalties. "Anyone who suffers from cancer, or know someone who does, understands the fear and...

  • Lilly reiterated that it was disappointed and disagreed with the FDA assessment on baricitinib, particularly since the medicine won European approval. On a conference call with analysts, Lilly was asked whether it was likely in 2017 or 2018 to satisfy FDA concerns outlined in the letter denying approval. "We can't give an estimate on this year or next until we...